Fig. 1.
Drug retentiona up to 4 years in all patients (a) and those receiving first-line (b) and subsequent-line treatment (c) analyzed by Kaplan–Meier and Hall–Wellner methods to account for the varied follow-up periods of different patients due to the prospective, observational design of the KOBIO registry. Shading indicates 95% Hall–Wellner bands; + indicates censored patients. KOBIO Korean College of Rheumatology Biologics. aDefined as time to discontinuation or change of biologic therapy